Vaxcyte grants CMO RSUs, options on 140K shares

Vaxcyte granted its Chief Medical Officer a sizable mix of RSUs and stock options with time-based vesting tied to continued service.

Available on EDGAR 09/09/2026 - 05:40 PM EDT Accepted by SEC EDGAR 09/09/2026 - 05:40 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Vaxcyte, Inc. (PCVX) reported that Chief Medical Officer Luis Jodar received new equity awards on September 4, 2026. He was granted 52,632 restricted stock units, each representing one share of common stock, and a stock option for 88,254 shares at an exercise price of $61.16 per share, expiring September 4, 2036. The RSUs vest 25% on September 7, 2027 and 12.5% every six months thereafter, and the option vests 25% on August 31, 2027 and monthly thereafter, in each case subject to his continued service. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 140,886 shares

Grant/Award 2 txns

Insider Jodar Luis

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F2	88,254	$0.00	$0.00
Grant/Award	Common Stock F1	52,632	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 88,254 contracts (Direct); Common Stock — 52,632 shares (Direct)

Footnotes (2)

1. F1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2027 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.
2. F2. 1/4 of the shares subject to the option shall vest on August 31, 2027, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

Key Figures

RSUs granted: 52,632 units Option shares granted: 88,254 shares Option exercise price: $61.16 per share +3 more

6 metrics

RSUs granted 52,632 units Restricted stock units granted to Chief Medical Officer on September 4, 2026

Option shares granted 88,254 shares Shares underlying stock option granted on September 4, 2026

Option exercise price $61.16 per share Exercise price for the stock option granted to the Chief Medical Officer

Option expiration date September 4, 2036 Expiration of stock option covering 88,254 shares

Initial RSU vesting date September 7, 2027 25% of RSU shares vest on this date, subject to continued service

Initial option vesting date August 31, 2027 25% of option shares vest on this date, subject to continued service

Key Terms

restricted stock units ("RSUs"), contingent right, vest

3 terms

restricted stock units ("RSUs") financial

"Represents the number of shares of Common Stock underlying restricted stock units ("RSUs")."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

contingent right financial

"Each RSU represents the contingent right to receive one share"

vest financial

"The RSUs vest as to 1/4 of the shares subject to the award"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did Vaxcyte (PCVX) grant to its Chief Medical Officer?

On September 4, 2026, Vaxcyte granted Chief Medical Officer Luis Jodar 52,632 restricted stock units and a stock option covering 88,254 shares of common stock at an exercise price of $61.16 per share, as part of his equity compensation.

How do the new RSUs for Vaxcyte (PCVX) Chief Medical Officer vest?

The 52,632 RSUs granted to Chief Medical Officer Luis Jodar vest as follows: 25% of the shares on September 7, 2027 and 12.5% of the shares every six months thereafter, subject to his continuous service with Vaxcyte.

What is the vesting schedule of the new Vaxcyte (PCVX) stock option?

The stock option for 88,254 shares vests as follows: 25% of the shares on August 31, 2027, and 1/48 of the shares monthly thereafter, provided Chief Medical Officer Luis Jodar continues his service with Vaxcyte through each vesting date.

What is the exercise price and expiration date of the new Vaxcyte (PCVX) option?

Chief Medical Officer Luis Jodar’s new option has an exercise price of $61.16 per share and expires on September 4, 2036, giving him the right to purchase up to 88,254 shares of Vaxcyte common stock before that date, subject to vesting.

How many Vaxcyte (PCVX) shares does the Chief Medical Officer hold directly after these awards?

After the reported September 4, 2026 awards, Chief Medical Officer Luis Jodar directly holds 52,632 shares of Vaxcyte common stock through restricted stock units and has a stock option covering 88,254 additional shares, all subject to the described vesting schedules.

Were the Vaxcyte (PCVX) equity awards to the Chief Medical Officer made under a Rule 10b5-1 plan?

No. The filing states that no Rule 10b5-1 trading plan is reported in connection with the September 4, 2026 equity awards to Chief Medical Officer Luis Jodar.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jodar Luis

(Last) (First) (Middle)

C/O VAXCYTE, INC.

825 INDUSTRIAL ROAD, SUITE 300

(Street)

SAN CARLOS CALIFORNIA 94070

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Vaxcyte, Inc. [ PCVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/04/2026		A		52,632(1)	A	$0	52,632	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$61.16	09/04/2026		A		88,254		(2)	09/04/2036	Common Stock	88,254	$0	88,254	D

Explanation of Responses:

1. Represents the number of shares of Common Stock underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. The RSUs vest as to 1/4 of the shares subject to the award on September 7, 2027 and 1/8 of the shares every six months thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

2. 1/4 of the shares subject to the option shall vest on August 31, 2027, and 1/48 of the shares shall vest monthly thereafter, subject to Reporting Person's continuous service with the Issuer through each such date.

Remarks:

	Luis Jodar, by /s/ Peter N. Efremenko, Attorney-In-Fact	09/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)